



DAFTAR PUSTAKA

- Bhoi, D., 2012, Dietary Bioactive Compounds as Histone Deacetylase Inhibitor for Cancer Prevention, *Thesis*, National Institute of Technology, Rourkela, Odisha.
- Bassett-Shalome, A. & Barnett-Mathew, P.G., 2014, The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease, *Nutrients*, **6(10)**, 4273-4301.
- Batra, S., Sahu, R.P., Kandala, P.K., & Srivastava, S.K., 2010, Benzyl isothiocyanate mediated inhibition of histone deacetylase leads to NF- κ B turn off in human pancreatic carcinoma cells, *Molecular Cancer Therapeutics*, **9(6)**, 1596-1608.
- Bosch-Presegué L. & Vaguero, A., 2011, The Dual Role of Sirtuins in Cancer, *Genes Cancer*, **2(6)**, 648-662.
- Carafa, V., Nebbioso, A., & Altucci, L., 2012, Sirtuins & disease, The road ahead, *Frontiers in Pharmacology*, **3**, 4.
- Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., *et al.*, 2012, HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle, *Nature*, **489(7415)**, 313–317.
- De Ruijter, A.J.M., Van Gennip, A.H., Caron, H.N., Kemp, S., & Van Kuilenburg, A.B.P., 2003 Histone deacetylases (HDAs): characterization of the HDA family, *Biochemical Journal*: **370**, 737-749.
- Fahey, J.W., Zalcmann, A.T., & Talalay, P., 2001, The chemical diversity and distribution of glucosinolates and isothiocyanates among plants, *Phytochemistry*, **56(1)**, 5-51.
- Fischer, A., Sanabenesi, F., Mungenast, A., & Tsai, L., 2010, Targeting the correct HDAC(s) to treat cognitive disorders, *Trends in Pharmacological Sciences*, **31(12)**, 605-617.
- Gandjar, I.G. & Rohman, A., 2007, *Kimia Farmasi Analisis*, Yogyakarta: Pustaka Pelajar.
- Ghozali, I., 2013, *Aplikasi Analisis Multivariat dengan Program IBM SPSS*, Yogyakarta: Badan Penerbit BPFE.
- Gloghini, A., Buglio, D., Khaskhely, N. M., Georgakis, G., Orłowski, R. Z., Neelapu, S.S., *et al.*, 2009, Expression of histone deacetylases in lymphoma:



- implication for the development of selective inhibitors, *British Journal of Haematology*, **147(4)**, 515–525.
- Hecht, S.S., 1999, Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism, *The Journal of Nutrition*, **129(3)**, 768s-774s.
- Hecht, S.S., 2000, Inhibition of carcinogenesis by isothiocyanates, *Drug Metabolism*, **32(3-4)**, 395-411.
- Inkster, B., Strijbis, E.M., Vounou, M., Kappos, L., Radue, E.W., Matthews, P.M., *et al.*, 2013, Histone deacetylase gene variants predict brain volume changes in multiple sclerosis, *Neurobiology of Aging*, **34(1)**, 238–247.
- Ito, K., Barnes, P.J., & Adcock, I.M., 2000, Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12, *Molecular and Cell Biology*, **20(18)**, 6891-6903.
- Jin, K.L., Pak, J.H., Park, J.Y., Choi, W.H., Lee, J.Y., Kim, J.H., *et al.*, 2008, Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues, *Journal of Gynecologic Oncology*, **19(3)**, 185–190.
- Kawalec, P., Lopuch, S., & Mikrut, A., 2015, Effectiveness of Targeted Therapy in Patients with Previously Untreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis, *Clinical Breast Cancer*, **15(2)**, 90-100.
- Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khrantsov, N., *et al.*, 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors, *Biochemical Journal*, **409(2)**, 581–589.
- Kim, T., Park, J.K., Kim, H.J., Chung, J.H., & Kim, J.W., 2010, Association of histone deacetylase genes with schizophrenia in Korean population, *Psychiatry Research*, **178(2)**, 266–269.
- Lutz, M.I., Milenkovic, I., Regelsberger, G., & Kovacs, G.G., 2014, Distinct patterns of sirtuin expression during progression of Alzheimer's disease, *Neuromolecular Medicine*, **16(2)**, 405–414.
- Mai, A., Rotili, D., Pezzi, R., Bottoni, P., Scatena, R., Meraner, J., *et al.*, 2005, Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates, *Bioorganic and Medicinal Chemistry Letters*, **15(21)**, 4656-4661.
- Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., *et al.*, 2013, HDAC4 reduction: A novel therapeutic strategy to target



- cytoplasmic huntingtin and ameliorate neurodegeneration, *PLOS Biology*, **11(11)**, e1001717.
- Muth, J.E.D., 1999, *Basic Statistics and Pharmaceutical Statistical Applications*, New York: Marcel Dekker Inc.
- Newkirk, T.L., Bowers, A.A., & Williams, R.M., 2009, Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors, *Natural Product Reports*, **26(10)**, 1293–1320.
- Noh, H., Oh, E.Y., Seo, J.Y., Yu, M.R., Kim, Y.O., Ha, H., *et al.*, 2009, Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor- β 1-induced renal injury, *American Journal of Physiology Renal Physiology*, **297(3)**, F729–F739.
- Novakovic, A., Gojkovic-Bukarica, L., Peric, M., Nezic, D., Djukanovic, B., Markovic-Lipkovski, J., *et al.*, 2006, The mechanism of endothelium independent relaxation induced by the wine polyphenol resveratrol in human internal mammary artery, *Journal of Pharmacological Sciences*, **101(1)**, 85–90.
- Ozdog, H., Teschendorff, A., Ahmed, A., Hyland, S., Blenkiron, C., Bobrow, L., *et al.*, 2006, Differential expression of selected histone modifier genes in human solid cancers, *BMC Genomics*, **7**, 90.
- Riggs, M.G., Whittaker, R.G., Neumann, J.R., & Ingram, V.M., 1997, *n*-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells, *Nature*, **268**, 462–464.
- Ropero, S., Fraga, M.F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., *et al.*, 2006, A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition, *Nature Genetics*, **38(5)**, 566–569.
- Ropero, S. & Esteller, M., 2007, The role of histone deacetylases (HDAs) in human cancer, *Molecular Oncology*, **1**, 19-25.
- Sambucetti, L.C., Fischer, D.D, Zabludoff, S., Kwon, P.O., Chamberlin, H., Trogani, N., *et al.*, 1999, Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects, *The Journal of Biological Chemistry*, **274(49)**, 34940–34947.
- Simois-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.A., & Cuendet, M., 2013, HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs?, *Molecular Neurodegeneration*, **8**, 7.



- Sjöblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., *et al.*, 2006, The consensus coding sequences of human breast and colorectal cancers, *Science*, **314(5797)**, 268–274.
- Strahl B.D. & Allis C.D., 2000, The language of covalent histone modifications. *Nature*, **403(6765)**, 41-45.
- Vigushin, D.M., Ali, S., Pace, P.E., Mirsaidi, N., Ito, K., Adcock, I., *et al.*, 2001. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo, *Clinical Cancer Research*, **7(4)**, 971-976.
- Wang, J.C., Kafeel, M.I., Avezbakiyev, B., Chen, C., Sun, Y., Rathnasabapathy, C., *et al.*, 2011, Histone deacetylase in chronic lymphocytic leukemia, *Oncology*, **81(5-6)**, 325–329.
- Zeng, Z., Liao, R., Yao, Z., Zhou, W., Ye, P., Zheng, X., *et al.*, 2014, Three single nucleotide variants of the *HDAC* gene are associated with type 2 diabetes mellitus in a Chinese population: A community-based case-control study, *Gene*, **533(1)**, 427–433.
- Zhang, R., Sivakumar, L., Ian H, & Sanjay, K.S., 2006, Benzyl isothiocyanate-induced DNA damage causes G₂/M cell cycle arrest and apoptosis in human pancreatic cancer cells, *The Journal of Nutrition*, **136(11)**, 2728-2734.
- Zhang, L., Sheng, S., & Qin, C., 2013, The role of HDAC6 in Alzheimer's disease, *Journal Alzheimer's Disease*, **33(2)**, 283–295.